Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup - a retrospective integrated clinical and molecular analysis
Standard
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup - a retrospective integrated clinical and molecular analysis. / Thompson, Eric M; Hielscher, Thomas; Bouffet, Eric; Remke, Marc; Luu, Betty; Gururangan, Sridharan; McLendon, Roger E; Bigner, Darell D; Lipp, Eric S; Perreault, Sebastien; Cho, Yoon-Jae; Grant, Gerald; Kim, Seung-Ki; Lee, Ji-Yeoun; Rao, Amulya A Nageswara; Giannini, Caterina; Li, Kay Ka Wai; Ng, Ho-Keung; Yao, Yu; Kumabe, Toshihiro; Tominaga, Teiji; Grajkowska, Wieslawa A; Perek-Polnik, Marta; Low, David C Y; Seow, Wan Tew; Chang, Kenneth T E; Mora, Jaume; Pollack, Ian F; Hamilton, Ronald L; Leary, Sarah; Moore, Andrew S; Ingram, Wendy J; Hallahan, Andrew R; Jouvet, Anne; Fèvre-Montange, Michelle; Vasiljevic, Alexandre; Faure-Conter, Cecile; Shofuda, Tomoko; Kagawa, Naoki; Hashimoto, Naoya; Jabado, Nada; Weil, Alexander G; Gayden, Tenzin; Wataya, Takafumi; Shalaby, Tarek; Grotzer, Michael; Zitterbart, Karel; Sterba, Jaroslav; Kren, Leos; Hortobágyi, Tibor; Klekner, Almos; László, Bognár; Pócza, Tímea; Hauser, Peter; Schüller, Ulrich; Jung, Shin; Jang, Woo-Youl; French, Pim J; Kros, Johan M; van Veelen, Marie-Lise C; Massimi, Luca; Leonard, Jeffrey R; Rubin, Joshua B; Vibhakar, Rajeev; Chambless, Lola B; Cooper, Michael K; Thompson, Reid C; Faria, Claudia C; Carvalho, Alice; Nunes, Sofia; Pimentel, José; Fan, Xing; Muraszko, Karin M; López-Aguilar, Enrique; Lyden, David; Garzia, Livia; Shih, David J H; Kijima, Noriyuki; Schneider-Fresenius, Christian; Adamski, Jennifer; Northcott, Paul A; Kool, Marcel; Jones, David T W; Chan, Jennifer A; Nikolic, Ana; Garre, Maria-Luisa; Van Meir, Erwin G; Osuka, Satoru; Olson, Jeffrey J; Jahangiri, Arman; Castro, Brandyn A; Gupta, Nalin; Weiss, William A; Moxon-Emre, Iska; Mabbott, Donald J; Lassaletta, Alvaro; Hawkins, Cynthia E; Tabori, Uri; Drake, James; Kulkarni, Abhaya; Dirks, Peter B; Rutka, James T; Korshunov, Andrey; Pfister, Stefan M; Packer, Roger J; Ramaswamy, Vijay; Taylor, Michael D.
In: LANCET ONCOL, Vol. 17, No. 4, 04.2016, p. 484-95.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup - a retrospective integrated clinical and molecular analysis
AU - Thompson, Eric M
AU - Hielscher, Thomas
AU - Bouffet, Eric
AU - Remke, Marc
AU - Luu, Betty
AU - Gururangan, Sridharan
AU - McLendon, Roger E
AU - Bigner, Darell D
AU - Lipp, Eric S
AU - Perreault, Sebastien
AU - Cho, Yoon-Jae
AU - Grant, Gerald
AU - Kim, Seung-Ki
AU - Lee, Ji-Yeoun
AU - Rao, Amulya A Nageswara
AU - Giannini, Caterina
AU - Li, Kay Ka Wai
AU - Ng, Ho-Keung
AU - Yao, Yu
AU - Kumabe, Toshihiro
AU - Tominaga, Teiji
AU - Grajkowska, Wieslawa A
AU - Perek-Polnik, Marta
AU - Low, David C Y
AU - Seow, Wan Tew
AU - Chang, Kenneth T E
AU - Mora, Jaume
AU - Pollack, Ian F
AU - Hamilton, Ronald L
AU - Leary, Sarah
AU - Moore, Andrew S
AU - Ingram, Wendy J
AU - Hallahan, Andrew R
AU - Jouvet, Anne
AU - Fèvre-Montange, Michelle
AU - Vasiljevic, Alexandre
AU - Faure-Conter, Cecile
AU - Shofuda, Tomoko
AU - Kagawa, Naoki
AU - Hashimoto, Naoya
AU - Jabado, Nada
AU - Weil, Alexander G
AU - Gayden, Tenzin
AU - Wataya, Takafumi
AU - Shalaby, Tarek
AU - Grotzer, Michael
AU - Zitterbart, Karel
AU - Sterba, Jaroslav
AU - Kren, Leos
AU - Hortobágyi, Tibor
AU - Klekner, Almos
AU - László, Bognár
AU - Pócza, Tímea
AU - Hauser, Peter
AU - Schüller, Ulrich
AU - Jung, Shin
AU - Jang, Woo-Youl
AU - French, Pim J
AU - Kros, Johan M
AU - van Veelen, Marie-Lise C
AU - Massimi, Luca
AU - Leonard, Jeffrey R
AU - Rubin, Joshua B
AU - Vibhakar, Rajeev
AU - Chambless, Lola B
AU - Cooper, Michael K
AU - Thompson, Reid C
AU - Faria, Claudia C
AU - Carvalho, Alice
AU - Nunes, Sofia
AU - Pimentel, José
AU - Fan, Xing
AU - Muraszko, Karin M
AU - López-Aguilar, Enrique
AU - Lyden, David
AU - Garzia, Livia
AU - Shih, David J H
AU - Kijima, Noriyuki
AU - Schneider-Fresenius, Christian
AU - Adamski, Jennifer
AU - Northcott, Paul A
AU - Kool, Marcel
AU - Jones, David T W
AU - Chan, Jennifer A
AU - Nikolic, Ana
AU - Garre, Maria-Luisa
AU - Van Meir, Erwin G
AU - Osuka, Satoru
AU - Olson, Jeffrey J
AU - Jahangiri, Arman
AU - Castro, Brandyn A
AU - Gupta, Nalin
AU - Weiss, William A
AU - Moxon-Emre, Iska
AU - Mabbott, Donald J
AU - Lassaletta, Alvaro
AU - Hawkins, Cynthia E
AU - Tabori, Uri
AU - Drake, James
AU - Kulkarni, Abhaya
AU - Dirks, Peter B
AU - Rutka, James T
AU - Korshunov, Andrey
AU - Pfister, Stefan M
AU - Packer, Roger J
AU - Ramaswamy, Vijay
AU - Taylor, Michael D
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/4
Y1 - 2016/4
N2 - BACKGROUND: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensified chemoradiotherapy. All previous studies assessing the clinical importance of extent of resection have not accounted for molecular subgroup. We analysed the prognostic value of extent of resection in a subgroup-specific manner.METHODS: We retrospectively identified patients who had a histological diagnosis of medulloblastoma and complete data about extent of resection and survival from centres participating in the Medulloblastoma Advanced Genomics International Consortium. We collected from resections done between April, 1997, and February, 2013, at 35 international institutions. We established medulloblastoma subgroup affiliation by gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. We classified extent of resection on the basis of postoperative imaging as gross total resection (no residual tumour), near-total resection (<1·5 cm(2) tumour remaining), or sub-total resection (≥1·5 cm(2) tumour remaining). We did multivariable analyses of overall survival and progression-free survival using the variables molecular subgroup (WNT, SHH, group 4, and group 3), age (<3 vs ≥3 years old), metastatic status (metastases vs no metastases), geographical location of therapy (North America/Australia vs rest of the world), receipt of chemotherapy (yes vs no) and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation). The primary analysis outcome was the effect of extent of resection by molecular subgroup and the effects of other clinical variables on overall and progression-free survival.FINDINGS: We included 787 patients with medulloblastoma (86 with WNT tumours, 242 with SHH tumours, 163 with group 3 tumours, and 296 with group 4 tumours) in our multivariable Cox models of progression-free and overall survival. We found that the prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. We identified a progression-free survival benefit for gross total resection over sub-total resection (hazard ratio [HR] 1·45, 95% CI 1·07-1·96, p=0·16) but no overall survival benefit (HR 1·23, 0·87-1·72, p=0·24). We saw no progression-free survival or overall survival benefit for gross total resection compared with near-total resection (HR 1·05, 0·71-1·53, p=0·8158 for progression-free survival and HR 1·14, 0·75-1·72, p=0·55 for overall survival). No significant survival benefit existed for greater extent of resection for patients with WNT, SHH, or group 3 tumours (HR 1·03, 0·67-1·58, p=0·89 for sub-total resection vs gross total resection). For patients with group 4 tumours, gross total resection conferred a benefit to progression-free survival compared with sub-total resection (HR 1·97, 1·22-3·17, p=0·0056), especially for those with metastatic disease (HR 2·22, 1·00-4·93, p=0·050). However, gross total resection had no effect on overall survival compared with sub-total resection in patients with group 4 tumours (HR 1·67, 0·93-2·99, p=0·084).INTERPRETATION: The prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. Although maximum safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high because there is no definitive benefit to gross total resection compared with near-total resection.FUNDING: Canadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in Childhood Cancer Research.
AB - BACKGROUND: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensified chemoradiotherapy. All previous studies assessing the clinical importance of extent of resection have not accounted for molecular subgroup. We analysed the prognostic value of extent of resection in a subgroup-specific manner.METHODS: We retrospectively identified patients who had a histological diagnosis of medulloblastoma and complete data about extent of resection and survival from centres participating in the Medulloblastoma Advanced Genomics International Consortium. We collected from resections done between April, 1997, and February, 2013, at 35 international institutions. We established medulloblastoma subgroup affiliation by gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. We classified extent of resection on the basis of postoperative imaging as gross total resection (no residual tumour), near-total resection (<1·5 cm(2) tumour remaining), or sub-total resection (≥1·5 cm(2) tumour remaining). We did multivariable analyses of overall survival and progression-free survival using the variables molecular subgroup (WNT, SHH, group 4, and group 3), age (<3 vs ≥3 years old), metastatic status (metastases vs no metastases), geographical location of therapy (North America/Australia vs rest of the world), receipt of chemotherapy (yes vs no) and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation). The primary analysis outcome was the effect of extent of resection by molecular subgroup and the effects of other clinical variables on overall and progression-free survival.FINDINGS: We included 787 patients with medulloblastoma (86 with WNT tumours, 242 with SHH tumours, 163 with group 3 tumours, and 296 with group 4 tumours) in our multivariable Cox models of progression-free and overall survival. We found that the prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. We identified a progression-free survival benefit for gross total resection over sub-total resection (hazard ratio [HR] 1·45, 95% CI 1·07-1·96, p=0·16) but no overall survival benefit (HR 1·23, 0·87-1·72, p=0·24). We saw no progression-free survival or overall survival benefit for gross total resection compared with near-total resection (HR 1·05, 0·71-1·53, p=0·8158 for progression-free survival and HR 1·14, 0·75-1·72, p=0·55 for overall survival). No significant survival benefit existed for greater extent of resection for patients with WNT, SHH, or group 3 tumours (HR 1·03, 0·67-1·58, p=0·89 for sub-total resection vs gross total resection). For patients with group 4 tumours, gross total resection conferred a benefit to progression-free survival compared with sub-total resection (HR 1·97, 1·22-3·17, p=0·0056), especially for those with metastatic disease (HR 2·22, 1·00-4·93, p=0·050). However, gross total resection had no effect on overall survival compared with sub-total resection in patients with group 4 tumours (HR 1·67, 0·93-2·99, p=0·084).INTERPRETATION: The prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. Although maximum safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high because there is no definitive benefit to gross total resection compared with near-total resection.FUNDING: Canadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in Childhood Cancer Research.
KW - Adult
KW - Brain Neoplasms
KW - Canada
KW - Child
KW - Child, Preschool
KW - Combined Modality Therapy
KW - Disease Progression
KW - Disease-Free Survival
KW - Female
KW - Humans
KW - Infant
KW - Magnetic Resonance Imaging
KW - Male
KW - Medulloblastoma
KW - Prognosis
KW - Retrospective Studies
KW - Journal Article
U2 - 10.1016/S1470-2045(15)00581-1
DO - 10.1016/S1470-2045(15)00581-1
M3 - SCORING: Journal article
C2 - 26976201
VL - 17
SP - 484
EP - 495
JO - LANCET ONCOL
JF - LANCET ONCOL
SN - 1470-2045
IS - 4
ER -